000130667 001__ 130667
000130667 005__ 20240228143452.0
000130667 0247_ $$2doi$$a10.1038/srep29731
000130667 0247_ $$2pmid$$apmid:27431859
000130667 0247_ $$2pmc$$apmc:PMC4949472
000130667 037__ $$aDKFZ-2017-05745
000130667 041__ $$aeng
000130667 082__ $$a000
000130667 1001_ $$aThimsen, Vivian$$b0
000130667 245__ $$aEpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts.
000130667 260__ $$aLondon$$bNature Publishing Group$$c2016
000130667 3367_ $$2DRIVER$$aarticle
000130667 3367_ $$2DataCite$$aOutput Types/Journal article
000130667 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522147660_11125
000130667 3367_ $$2BibTeX$$aARTICLE
000130667 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130667 3367_ $$00$$2EndNote$$aJournal Article
000130667 520__ $$aThe epithelial cell adhesion molecule (EpCAM) is a type I glycoprotein located on the surface of epithelial cells. It is strongly expressed in many neoplasms and already used in the diagnosis and distinction of various tumour subtypes. Comparative studies about EpCAM expression in cystic sellar lesions are lacking. Therefore, we analysed its distribution pattern in adamantinomatous (aCP) and papillary (pCP) craniopharyngiomas (CP) and Rathke's Cleft Cysts (RCC) using immunohistochemistry and gene expression profiling. Whereas the protein was not detectable in pCP (n = 10), all aCP (n = 64) showed distinct staining patterns. The vast majority of RCC (n = 10) also appeared positive, but these displayed notably lower labeling scores. Additionally, significantly higher mRNA levels were detectable in aCP (n = 19) when compared to pCP (n = 10) (p = 9.985(-8)). Furthermore, pediatric aCP cases, in general, exhibited stronger EpCAM staining levels compared to adult ones (p = 0.015). However, we were not able to verify this result on mRNA level. In summary, our findings demonstrate that EpCAM can be used as an additional distinction-marker for cystic lesions of the sellar region. Its unknown function in aCP and the presence of an approved monoclonal bispecific trifunctional antibody for cancer therapy are interesting starting points for further studies.
000130667 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000130667 588__ $$aDataset connected to CrossRef, PubMed,
000130667 7001_ $$aHölsken, Annett$$b1
000130667 7001_ $$aBuchfelder, Michael$$b2
000130667 7001_ $$aFlitsch, Jörg$$b3
000130667 7001_ $$aFahlbusch, Rudolf$$b4
000130667 7001_ $$aStefanits, Harald$$b5
000130667 7001_ $$aLosa, Marco$$b6
000130667 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b7$$udkfz
000130667 7001_ $$aBuslei, Rolf$$b8
000130667 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/srep29731$$gVol. 6, no. 1, p. 29731$$n1$$p29731$$tScientific reports$$v6$$x2045-2322$$y2016
000130667 909CO $$ooai:inrepo02.dkfz.de:130667$$pVDB
000130667 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000130667 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000130667 9141_ $$y2016
000130667 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2015
000130667 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130667 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130667 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130667 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000130667 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000130667 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000130667 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130667 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130667 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130667 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130667 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000130667 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000130667 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130667 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bSCI REP-UK : 2015
000130667 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000130667 980__ $$ajournal
000130667 980__ $$aVDB
000130667 980__ $$aI:(DE-He78)B062-20160331
000130667 980__ $$aUNRESTRICTED